Merck, Pfizer and Verastem join forces on testing avelumab combo

3 March 2016

Germany’s Merck KGaA (MRK: DE), US pharma giant Pfizer (NYSE: PFE) and cancer drug developer Verastem (Nasdaq: VSTM) have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063 (defactinib), an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer.

Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.

Merck and Pfizer have existing agreements on the development of avelumab, which has gained US Breakthrough Therapy designation for the treatment of a rare skin cancer (The Pharma Letter November 19, 2015). The two companies also have an accord with Syndax Pharmaceuticals to evaluate a potential combination therapy of avelumab and entinostat for ovarian cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK